Evidence map›Paper›PMID 41664603›Full record

ReviewExpert review of clinical pharmacology

Vaping Δ

Ashleigh C Block, Danielle M Smith, Maciej L Goniewicz

Abstract readReview
In one paragraph

Review in Expert review of clinical pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ashleigh C BlockDepartment of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, NY , USA.
Danielle M SmithDepartment of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, NY , USA.
Maciej L GoniewiczDepartment of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, NY , USA.

Funding

Assessing pharmacokinetic and pharmacodynamic variability of Δ9-tetrahydrocannabinol delivered from vaping products with and without concurrent use of nicotineR01DA057228 · NIDA · ROSWELL PARK CANCER INSTITUTE CORP · PI Maciej Lukasz Goniewicz, Danielle Smith · 2022 to 2026
$3.4M
NIDA NIH HHS R01 DA057228
6 · The paper itself

Abstract

introductionLittle is known about the pharmacokinetics (PK) and pharmacodynamics (PD) of Δ AREAS COVERED: Currently, no human studies have elucidated the PK/PD profile of Δ EXPERT OPINION: While more potent than smoked cannabis, vaped liquid formulations with Δ

Indexed as

DronabinolVapingAerosolsAnimalsBiological AvailabilityElectronic Nicotine Delivery SystemsHumansNicotineUnited StatesAerosolsDronabinolNicotineBehavioral pharmacologycannabiscannabis regulationpharmacodynamicspharmacokineticspublic healthvapingΔ9-tetrahydrocannabinol

Identifiers

PMID41664603
PMCPMC13251897

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.